CORCEPT THERAPEUTICS INC 4

CFO Atabak Mokari exercised 40,000 Corcept Therapeutics options and sold 40,000 CORT common shares on 2026-07-15 for about $3.5 million in total proceeds under a 10b5-1 plan.

On July 15, 2026, Corcept Therapeutics Inc. CFO Atabak Mokari exercised two tranches of stock options for a total of 40,000 common shares at strike prices of $19.26 and $23.06, then sold an aggregate 40,000 shares in multiple open-market transactions executed under a prearranged Rule 10b5-1 trading plan at weighted average prices ranging from approximately $86.78 to $89.43 per share, resulting in gross sale proceeds of roughly $3.5 million; following these exercises and sales, he reported direct ownership of 16,130 common shares (including 1,409 unvested RSU shares) and the related options were fully exercised and reduced accordingly.

Filing Facts

CIK

1088856

Ticker

CORT

Form

4

Source Type

fda

Accession

0001193125-26-308058

Alert Tier

7